Three-dimensional
(3D) in vitro cell and tissue
culture models, particularly for the central nervous system, allow
for the exploration of mechanisms of organ development, cellular interactions,
and disease progression within defined environments. Here, we describe
the development and characterization of human 3D tissue models that
promote the differentiation and long-term survival of functional neural
networks. This work builds upon previous work where primary rodent
neurons were successfully grown in a similar 3D system. The model was adapted to human induced pluripotent
stem cells, allowing for a more direct exploration of the human condition.
These tissue cultures show diverse cell populations, including neurons
and astroglial cells, interacting in 3D and exhibit spontaneous neural
activity confirmed through electrophysiological recordings and calcium
imaging over at least nine months. This approach allows for the direct
integration of pluripotent stem cells into the 3D construct, bypassing
early neural differentiation steps (embryoid bodies and neural rosettes).
The streamlined process, in combination with the longevity of the
cultures, provides a system that can be manipulated to support a variety
of experimental applications, including the study of network development,
maturation, plasticity, and/or degeneration. This tissue model was
tested with stem cells derived from healthy individuals as well as
Alzheimer’s and Parkinson’s disease patients. We observed
similar growth and gene expression, which indicates the feasibility
of generating patient-derived brain tissue models. These could be
used to uncover early stage biomarkers of the disease state, in turn
supporting earlier diagnosis and improving understanding of disease
progression. With additional model development, this approach would
have potential use for investigating drug targets in neurodegenerative
diseases.
Glioblastoma (GBM) is the most common form of brain cancer. Even with aggressive treatment, tumor recurrence is almost universal and patient prognosis is poor because many GBM cell subpopulations, especially the mesenchymal and glioma stem cell populations, are resistant to temozolomide (TMZ), the most commonly used chemotherapeutic in GBM. For this reason, there is an urgent need for the development of new therapies that can more effectively treat GBM. Several recent studies have indicated that high expression of connexin 43 (Cx43) in GBM is associated with poor patient outcomes. It has been hypothesized that inhibition of the Cx43 hemichannels could prevent TMZ efflux and sensitize otherwise resistance cells to the treatment. In this study, we use a three-dimensional organoid model of GBM to demonstrate that combinatorial treatment with TMZ and αCT1, a Cx43 mimetic peptide, significantly improves treatment efficacy in certain populations of GBM. Confocal imaging was used to visualize changes in Cx43 expression in response to combinatorial treatment. These results indicate that Cx43 inhibition should be pursued further as an improved treatment for GBM.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.